Werewolf Therapeutics (NASDAQ:HOWL) Rating Lowered to “Hold” at Zacks Research

Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday, Zacks reports.

HOWL has been the subject of a number of other reports. Weiss Ratings upgraded shares of Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 10th. Wall Street Zen upgraded Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $4.00.

Werewolf Therapeutics Trading Up 1.9%

Werewolf Therapeutics stock opened at $1.09 on Tuesday. Werewolf Therapeutics has a 1-year low of $0.27 and a 1-year high of $1.27. The firm has a market capitalization of $52.97 million, a PE ratio of -1.43 and a beta of 0.55. The firm’s 50 day simple moving average is $0.98 and its 200 day simple moving average is $0.69.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Squarepoint Ops LLC bought a new stake in Werewolf Therapeutics during the second quarter valued at approximately $37,000. BlackRock Inc. purchased a new position in Werewolf Therapeutics in the 2nd quarter worth approximately $37,000. Vilga Financial Planning LLC bought a new position in shares of Werewolf Therapeutics in the 3rd quarter worth $49,000. StoneX Group Inc. increased its holdings in shares of Werewolf Therapeutics by 174.3% in the 3rd quarter. StoneX Group Inc. now owns 54,856 shares of the company’s stock worth $51,000 after buying an additional 34,856 shares during the last quarter. Finally, Vontobel Holding Ltd. bought a new position in shares of Werewolf Therapeutics in the 3rd quarter worth $55,000. 64.84% of the stock is currently owned by institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer treatments that stimulate the immune system. The company’s approach is designed to activate immune responses within the tumor microenvironment while limiting exposure to healthy tissues.

Werewolf’s technology platform, known as INDUKINE, uses conditionally activated cytokines. These therapeutic proteins are intended to remain inactive in the bloodstream and become activated primarily in tumors, where they may help recruit and enhance immune cells to attack cancer.